Moderna booster evidence to support the booster, notably the half-dose booster’s safety data
was thin, according to panel members. However, in the face of a continuing pandemic and evidence that at least some at-risk persons may acquire major breakthrough cases, they eventually concluded that it was good enough.
The fact that many patients with weakened immune systems have already received a full third dosage of the Moderna booster injection with no obvious issues pleased the doctors.
“These are exceptional times, and we have to deal with flawed data,” said Eric Rubin, a speaker from Harvard’s T.H.
Chan School of Public Health, expressing the sentiments of many panelists.
The FDA will now decide whether to give clearance or not. The FDA is not required to follow the recommendations of the advisory group and can decide whether or not to licence the booster and for which populations.
After the FDA takes action, the baton will be transferred to a separate advisory committee at the Centers for Disease Control and Prevention.
The Centers for Disease Control and Prevention’s advisory group on vaccination practises will meet on October 20 and 21. The group will develop its own booster recommendations and communicate them with CDC Director Rochelle Walensky, who will decide whether to accept them or come up with her own.
The FDA’s advisory group will meet again on Friday to discuss booster injections made by Johnson & Johnson
the third firm to have an approved COVID vaccine. Moderna and Pfizer-BioNTech vaccines have seen considerably more use than the single-shot J&J vaccination.
The conference will conclude with a discussion of how boosters might be combined with different vaccination injections.
Results from a government-sponsored study in the United States presented on Wednesday show that pairing COVID-19 vaccinations with a different booster results in the same amount of antibodies or more than just boosting the same dose.